iX Biopharma is exploring a spin-off of its pharmaceutical business, including medical cannabis, by way of a listing on the main board of The Stock Exchange of Hong Kong (HKEX).

In a filing to the Singapore Exchange (SGX) on July 12, the company disclosed it intends to restructure its pharmaceutical business to be held by Ligo Pharma, a wholly-owned subsidiary incorporated in the Cayman Islands.

Following the restructuring, the spin-off company will be engaged in manufacturing, research and development and sales of pharmaceutical and medicinal cannabis products. These activities are currently undertaken by iX Biopharma’s wholly-owned subsidiaries iX Syrinx, Arrow Property Trust, iX Biopharma, iX Biopharma Europe and iXB.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Related Stories

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook